Emergent BioSolutions (EBS) Other Non-Current Liabilities (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Other Non-Current Liabilities of $41.7 million for Q1 2026, up 17.8% year-over-year from $35.4 million in Q1 2025, and down 22.63% quarter-over-quarter from $53.9 million in Q4 2025.
Emergent BioSolutions (EBS) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $41.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 17.8% year-over-year to $41.7 million; the TTM figure through Mar 2026 stood at $41.7 million (up 17.8% YoY), while the FY2025 annual figure was $53.9 million, up 37.85% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $41.7 million, down from $53.9 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $58.5 million in Q2 2022, with the low at $23.4 million in Q2 2023.
- The 5-year median for Other Non-Current Liabilities is $39.1 million (2024), against an average of $38.3 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 1070.0% in 2022, then plunged 60.0% in 2023.
- Emergent BioSolutions' Other Non-Current Liabilities stood at $41.5 million in 2022, then tumbled by 30.36% to $28.9 million in 2023, then soared by 35.29% to $39.1 million in 2024, then jumped by 37.85% to $53.9 million in 2025, then decreased by 22.63% to $41.7 million in 2026.
- Business Quant data shows EBS's Other Non-Current Liabilities at $41.7 million in Q1 2026, $53.9 million in Q4 2025, and $42.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.40 Mn |
| Mar 31, 2026 | 41.70 Mn |
| Dec 31, 2025 | 53.90 Mn |
| Sep 30, 2025 | 42.60 Mn |
| Jun 30, 2025 | 39.50 Mn |
| Mar 31, 2025 | 35.40 Mn |
| Dec 31, 2024 | 39.10 Mn |
| Sep 30, 2024 | 35.80 Mn |
| Jun 30, 2024 | 25.70 Mn |
| Mar 31, 2024 | 28.00 Mn |
| Dec 31, 2023 | 28.90 Mn |
| Sep 30, 2023 | 31.30 Mn |
| Jun 30, 2023 | 23.40 Mn |
| Mar 31, 2023 | 24.10 Mn |
| Dec 31, 2022 | 41.50 Mn |
| Sep 30, 2022 | 52.30 Mn |
| Jun 30, 2022 | 58.50 Mn |
| Mar 31, 2022 | 49.30 Mn |
| Dec 31, 2021 | 69.50 Mn |
| Sep 30, 2021 | 58.70 Mn |